December 23, 2010 -- Xiangxue Pharmaceutical, which completed its IPO on Shenzhen’s GEM Exchange on December 15, expects to have a TCM treatment for Alzheimer’s disease on the market within three years. Wang Yonghui, Manager of Xiangxue, also disclosed plans to extend the indication of its major product, Anti-Virus Oral Liquid, to include conjunctivitis and HFMD (hand, foot and mouth) diseases. More details....
